Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2009:4:445-9.
doi: 10.2147/cia.s8200. Epub 2009 Nov 18.

Reducing hip fracture risk with risedronate in elderly women with established osteoporosis

Tahir Masud  1 , Michael McClung, Piet Geusens
Affiliations
Randomized Controlled Trial

Reducing hip fracture risk with risedronate in elderly women with established osteoporosis

Tahir Masud et al. Clin Interv Aging. 2009.

Abstract

Background: There is limited evidence to support the efficacy of current pharmaceutical agents in reducing the risk of hip fracture in older postmenopausal women with established osteoporosis.

Objective: To clarify the efficacy of risedronate in reducing the risk of hip fracture in elderly postmenopausal women aged > or = 70 years with established osteoporosis, i.e., those with bone mineral density-defined osteoporosis and a prevalent vertebral fracture.

Methods: Post hoc analysis of the Hip Intervention Program (HIP) study, a randomized controlled trial comparing risedronate with placebo for reducing the risk of hip fracture in elderly women. Women aged 70 to 100 years with established osteoporosis (baseline femoral neck T-score < or = -2.5 and > or =1 prior vertebral fracture) were included. The main outcome measure was 3-year hip fracture incidence in the risedronate and placebo groups.

Results: A total of 1656 women met the inclusion criteria. After 3 years, hip fracture had occurred in 3.8% of risedronate-treated patients and 7.4% of placebo-treated patients (relative risk 0.54; 95% confidence interval 0.32-0.91; P = 0.019).

Conclusion: Risedronate significantly reduced the risk of hip fracture in women aged up to 100 years with established osteoporosis.

Keywords: hip fracture; osteoporosis; postmenopausal; risedronate.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Study population. Abbreviations: BMD, bone mineral density; ITT, intention to treat.
See this image and copyright information in PMC

References

    1. van Helden S, van Geel AC, Geusens PP, Kessels A, Nieuwenhuijzen Kruseman AC, Brink PR. Bone and fall-related fracture risks in women and men with a recent clinical fracture. J Bone Joint Surg Am. 2008;90(2):241–248. - PubMed
    1. Sambrook P, Cooper C. Osteoporosis. Lancet. 2006;367(9527):2010–2018. - PubMed
    1. McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women Hip Intervention Program Study Group. N Engl J Med. 2001;344(5):333–340. - PubMed
    1. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356(18):1809–1822. - PubMed
    1. Boonen S, McClung MR, Eastell R, El-Hajj Fuleihan G, Barton IP, Delmas P. Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: implications for the use of antiresorptive agents in the old and oldest old. J Am Geriatr Soc. 2004;52(11):1832–1839. - PubMed

Publication types

MeSH terms